Analysts surveyed by Thomson Reuters are looking for life insurance giant MetLife Inc. (MET) to report that its earnings rose 80.0% from a year ago to $0.95 per share for the three months that ended in December. Revenue, however, is expected to total $12.6 billion, which is down 10.1% from a year ago, during a fourth quarter in which it offered guidance and declared a quarterly dividend. The analysts' forecast for the full year calls for earnings of $2.89 per share (-25.7%) on $48.3 billion in revenue (-5.3%). This New York-based insurer's earnings results have been better than expected in three of the past four quarters, beating estimates by as much as 20 cents per share.

MetLife's long-term EPS growth forecast is 10.7%, which is better than that of competitor Prudential Financial Inc. (PRU), and its earnings multiple is 8.8x. The First Call consensus recommendation has been to buy MET for more than 90 days, despite a recent downgrade of the stock. The mean price target is $42.87. Shares have been trading between $32.00 and $40.00 since August and closed the week at $35.32.

Analyst Upgrades

• FBR Capital upgraded New York Community Bancorp (NYB) to outperform from market perform following the FDIC-assisted acquisition of AmTrust. The firm raised its target price on shares to $16 from $11.
• Oppenheimer upgraded Brocade (BRCD) to outperform from perform to reflect valuation, low investor expectations, and the company's potential to gain market share in IP/Ethernet switching. The firm set a target price of $8.50 on shares.
• Stifel Nicolaus upgraded National Health Investors (NHI) to buy from hold following the announcement that the litigation vs. Care Foundation has been dismissed. The firm has a $37 target on the stock.
• American Express (AXP) was upgraded to neutral from underperform at BofA/Merrill.
• ACE Ltd. (ACE) was upgraded to buy from neutral at Goldman.
• Kohl's (KSS) was raised to outperform from neutral at Baird.

3M (NYSE: MMM) is one of those solid stocks that investors love to sock away in a core portfolio. It was down when pessimism about the economy was at its peak, but it's coming back now that Wall Street is becoming comfortable with the idea that the economic clouds will eventually give way to rays of macro sunshine.

Earlier in the week, 3M reported a great quarter. No, it wasn't so great on a comparable basis. The company, which counts Johnson & Johnson (NYSE: JNJ) and DuPont (NYSE: DD) as colleagues, suffered a decline of almost 6% on the top line in Q3. Earnings per share on an adjusted basis, which came in at $1.37 per share, were down 3.5%.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Altria Group Inc. (NYSE: MO) Q3 earnings beat by a penny but sales fell short of expectations; shares fell.
• AMR Corp. (NYSE: AMR) reported a Q3 net loss and plunging revenue but also raised $4 billion in cash.
• BB&T Corp. (NYSE: BBT) topped Q3 earnings expectations but said bad-loan provisions nearly doubled.
• Boeing Co. (NYSE: BA) missed estimates and posted a Q3 loss due to delays for a couple of jet products.
• Capital One Financial Corp. (NYSE: COF) shares rose after it reported better-than-expected Q3 numbers.
• Coca-Cola Co. (NYSE: KO) posted a better-than-expected Q3 profit but sales fell short, and shares fell.

Analyst upgrades:

• Citigroup upgraded Capital One (NYSE: COF) to Buy from Hold as it believes the credit cycle is starting to recover for U.S. credit cards and an improving economy will support bank credit stabilization. The firm raised its target on shares to $44 from $28.
• JPMorgan upgraded Morgan Stanley (NYSE: MS) to Overweight from Neutral on valuation and believes the stock market recovery will serve as a catalyst.
• Deutsche Bank upgraded F5 Networks (NASDAQ: FFIV) to Buy from Hold after its channel checks indicated a sooner-than-expected order ramp and stabilizing pricing trends. The firm raised its target on shares to $46 from $39.
• COTT Corp. (NYSE: COT) was upgraded to Buy from Neutral at UBS.
• Blackstone Group (NYSE: BX) was upgraded to Equal Weight from Underweight at Barclays.
• Illinois Tool Works (NYSE: ITW) was upgraded to Conviction Buy from Neutral at Goldman.

Du Pont reported better-than-expected Q2 earnings, but the report nevertheless did not overwhelm institutional investors, who've granted the company only a modest P/E of 14.

Even so, I'm Reiterating my Buy rating for E.I. du Pont de Nemours & Company (NYSE: DD), first recommended on April 22, 2009 at a price of $27.74. Here's why:

Excluding a 15-cent-per-share hit from restructuring charges, chemicals giant DuPont (NYSE: DD), yet another Dow component, said it would have earned 61 cents per share. That number bested consensus estimates for a 53-cent per share profit, but once again, the top-line number is cause for concern.

DuPont said its second-quarter profit dropped 61% to $417 million, or 46 cents per share, with revenue falling 24% to $7.09 billion. Analysts had expected the company to bring in $7.14 billion in revenue.

Although the headlines are screaming about how companies are beating their earnings estimates, little newsprint is being devoted to this quarter's real story.

That story is that revenues for many corporations are way down year over year, and more importantly, their top-line revenues are often coming in below Street estimates.

To be certain, there have been some real success stories so far in Q2, and we'll be talking about some of those in a moment. Moreover, it is always a good sign when companies beat their earnings estimates.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• AK Steel Holding Corp. (NYSE: AKS) posted a smaller-than-expected Q2 net loss as steel prices rise.
• Boston Scientific Corp. (NYSE: BSX) posted a better-than-expected Q2 profit on strong overseas sales.
• Caterpillar Inc. (NYSE: CAT) shares jumped after it beat earnings, missed revenues, and offered guidance.
• DuPont (NYSE: DD) shares declined after it posted a higher-than-expected profit but lower revenue.
• Eaton Corp. (NYSE: ETN) disappointing results were a sign that the bulls are in charge, said Jim Cramer.
• General Electric Co. (NYSE: GE) Q2 earnings and sales declined, dragged down by finance and NBC units.

Another stock leveraged to the oil market is Dupont (NYSE: DD). Because many of the company's products are derived from crude oil, rising oil prices negatively impact profit margins. The only recourse, then, is to raise the price for consumers. But doing so in this environment is unlikely given the weakness in the economy.

As a result, the dynamics of the market are such that profits for DD will be lower in the near term.

That puts the company in a bit of a Catch-22.

With such uncertainty, following an absolute return strategy continues to offer investors the biggest bang for their buck. There is no sense in guessing where the market will be down the road.

Instead, buy cheap stocks and sell stocks that are expensive. Then blend the two approaches together in one portfolio and chances are you'll make money.

Even with a huge rally in stocks, the S&P 500 ended the second quarter with a year-to-date gain of 1.78%. That is a vast improvement compared to the 11% loss at the end of the first quarter, but it's a minimal return for taking risk in the stock market.

Investors need to do better -- and they can.

"DuPont EI Neumours (NYSE: DD) is a world-class company with a world-class dividend yield," says growth & income expert Bryan Perry. Here's the latest from his The Cash Machine.

"Some of the biggest winners in a recovering economy are those stocks of companies engaged in the basic businesses such as industrial chemicals, plastics, and adhesives.

"The firm can implement price increases along the way, which could translate into phenomenal earnings surprises and set a stock like DuPont in motion higher.

Dow component DuPont (NYSE: DD) said today that it will eliminate another 2,000 jobs as part of its ongoing plan to cut costs. Previously, the blue chip slashed 2,500 employees and 4,000 contractor positions from its payroll back in December.

The company will take a second-quarter pre-tax restructuring charge of $340 million to $390 million as a result of the job cuts, though DuPont said it will save $225 million by the end of 2010.

The news pressured DD to a loss of 3% within the first hour of today's trading. The stock's pullback could potentially find a floor near its 20-day moving average; in collaboration with its 10-day counterpart, this trendline has guided the shares higher since early March.

3M (NYSE: MMM) had a not-that-great first quarter. The declines were significant and ugly. First, net sales plunged over 20%. Second, net income on an adjusted basis likewise spiraled out of control, declining over 40% to $0.81 per share. And no, that didn't meet expectations. Wall Street was looking for $0.86 per share. Sorry, gang.

You've got the dollar and the global recession to blame. Currency translations affected sales, and declines in economic activity didn't help much, either. Many people look to 3M as a staunch dividend play. As such, cash flow is important. Unfortunately, the statement of cash flows this quarter was hard to read. Net cash from operations decreased 30%, and free cash flow lost 35% of its value when compared to the year-ago period. Thankfully, there was enough free cash to cover the dividend.

Have institutional investors been overly harsh on Du Pont's (NYSE: DD) shares? Indeed they have. Here's why:

Look for DD's agriculture business to advance nicely, at double digit rates, in 2009, after a 22% gain in 2008. Pharmaceutical earnings are expected to be roughly flat. Look for raw material and energy costs to dip slightly in 2009.